Advertisement
Advertisement
SEER
Seer, Inc. Class A Common Stock
2.17
USDSponsored
-0.02
-0.91%
Aug 07, 15:59 UTC -4
Closed
Pre-Market
2.15
-0.02
-0.78%
SEER Earnings Reports
Positive Surprise Ratio
SEER beat 15 of 22 last estimates.
68%
Next Report
Tomorrow AMC
Date of Next Report
Aug 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
$3.62M
/-$0.27
Implied change from Q1 26 (Revenue/ EPS)
+29.65%
/-10.00%
Implied change from Q2 25 (Revenue/ EPS)
-10.61%
/-18.18%
Seer, Inc. Class A Common Stock earnings per share and revenue
On May 13, 2026, SEER reported earnings of -0.30 USD per share (EPS) for Q1 26, beating the estimate of -0.30 USD, resulting in a 0.30% surprise. Revenue reached 2.79 million, compared to an expected 3.67 million, with a -23.94% difference. The market reacted with a -1.13% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 3.62 million USD, implying an decrease of -10.00% EPS, and increase of 29.65% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
REGENXBIO Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.05
Actual
$0.43
Surprise
+626.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+5.15%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Genmab A/S ADS
Report Date
Aug 06, 2026 For Q2 26
Estimate
$3.59
Actual
$0.54
Surprise
-84.98%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$3.73
Actual
-$2.87
Surprise
+23.14%
Halozyme Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.87
Actual
$2.27
Surprise
+21.75%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
FAQ
What were Seer, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Seer, Inc. Class A Common Stock reported EPS of -$0.30, missing estimates by 0.3%, and revenue of $2.79M, -23.94% below expectations.
How did the market react to Seer, Inc. Class A Common Stock's Q1 2026 earnings?
The stock price moved down -1.13%, changed from $1.77 before the earnings release to $1.75 the day after.
When is Seer, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Aug 11, 2026.
What are the forecasts for Seer, Inc. Class A Common Stock's next earnings report?
Based on 3
analysts, Seer, Inc. Class A Common Stock is expected to report EPS of -$0.27 and revenue of $3.62M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement